Saturday, May 09, 2020 5:38:24 PM
Recent SNPX News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2024 02:21:09 PM
- Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength • PR Newswire (US) • 12/20/2024 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2024 10:06:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 10:00:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/07/2024 01:54:38 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 11/05/2024 11:01:09 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/28/2024 08:00:16 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 10/10/2024 09:11:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2024 08:30:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2024 08:54:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2024 01:00:53 PM
- Synaptogenix Announces $5.0 Million Financing • PR Newswire (US) • 09/11/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 09:00:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:30:55 PM
- Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury • PR Newswire (US) • 07/18/2024 01:00:00 PM
- Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis • PR Newswire (US) • 06/26/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:03:21 PM
- Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery • PR Newswire (US) • 05/07/2024 01:00:00 PM
- Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing • PR Newswire (US) • 04/24/2024 01:15:00 PM
- Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics • PR Newswire (US) • 04/09/2024 01:15:00 PM
- Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing • PR Newswire (US) • 04/03/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:16:19 PM
North Bay Resources Announces Operation of New Gravity Circuit at Bishop Gold Mill, California • NBRI • Jan 10, 2025 8:29 AM
Cannabix Technologies Announces Key Hardware Advancements to Marijuana Breathalyzer Technology • BLO • Jan 9, 2025 8:49 AM
UAV Corp. (UMAV) Further Reduces Authorized Shares to 500 Million • UMAV • Jan 8, 2025 2:27 PM
Fifty 1 Labs, Inc. Launches Dedicated Website for Shareholders and Investors, Company now current with OTC Markets • CAFI • Jan 7, 2025 9:00 AM
EzFill Holdings, Inc. Successfully Closes Acquisition of Shell Fleet, Accelerating Nationwide Mobile Fueling Expansion • EZFL • Jan 7, 2025 8:35 AM
CGRA Signs Binding Term Sheet to Merge With American Infrastructure Corporation, a Subsidiary of Nasdaq-listed American Resources Corporation (Nasdaq: AREC) • CGRA • Jan 6, 2025 10:31 AM